Our Paper about PIK3CA-Mutations is one of the most-cited papers in JCO.
Our paper about PIK3CA-Mutations from 2014 with 107 citations is one of the most-cited Paper in Journal of Clinical Oncology. We are very proud about this confirmation of the relevance of your research.
"PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer."
J Clin Oncol. 2014 Oct 10;32(29):3212-20. doi: 10.1200/JCO.2014.55.7876. Epub 2014 Sep 8.
GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440